Evidence map›Paper›PMID 34417540›Full record

ArticleScientific reports2021

Uridine treatment prevents myocardial injury in rat models of acute ischemia and ischemia/reperfusion by activating the mitochondrial ATP-dependent potassium channel.

Irina B Krylova, Elena N Selina, Valentina V Bulion, Olga M Rodionova, Natalia R Evdokimova, Natalia V Belosludtseva, Maria I Shigaeva, Galina D Mironova

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. The Role of Uridine in Health and Disease.Journal of inflammation research · 2025
    Review
  5. Article
  6. Article
  7. Ferroptosis inhibitors: past, present and future.Frontiers in pharmacology · 2024
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Irina B KrylovaDepartment of Neuropharmacology, Federal State Budgetary Scientific Institution, Institute of Experimental Medicine, St. Petersburg, Russia, 197376. irinakrylova@mail.ru.
Elena N SelinaDepartment of Neuropharmacology, Federal State Budgetary Scientific Institution, Institute of Experimental Medicine, St. Petersburg, Russia, 197376.
Valentina V BulionDepartment of Neuropharmacology, Federal State Budgetary Scientific Institution, Institute of Experimental Medicine, St. Petersburg, Russia, 197376.
Olga M RodionovaDepartment of Neuropharmacology, Federal State Budgetary Scientific Institution, Institute of Experimental Medicine, St. Petersburg, Russia, 197376.
Natalia R EvdokimovaDepartment of Neuropharmacology, Federal State Budgetary Scientific Institution, Institute of Experimental Medicine, St. Petersburg, Russia, 197376.
Natalia V BelosludtsevaLaboratory of Mitochondrial Transport, Institute of Theoretical and Experimental Biophysics of Russian Academy of Sciences, Pushchino, Moscow Region, Russia, 142290.
Maria I ShigaevaLaboratory of Mitochondrial Transport, Institute of Theoretical and Experimental Biophysics of Russian Academy of Sciences, Pushchino, Moscow Region, Russia, 142290.
Galina D MironovaLaboratory of Mitochondrial Transport, Institute of Theoretical and Experimental Biophysics of Russian Academy of Sciences, Pushchino, Moscow Region, Russia, 142290. mironova40@mail.ru.
Institute of Experimental Medicine · RUInstitute of Theoretical and Experimental Biophysics · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The effect of uridine on the myocardial ischemic and reperfusion injury was investigated. A possible mechanism of its cardioprotective action was established. Two rat models were used: (1) acute myocardial ischemia induced by occlusion of the left coronary artery for 60 min; and (2) myocardial ischemia/reperfusion with 30-min ischemia and 120-min reperfusion. In both models, treatment with uridine (30 mg/kg) prevented a decrease in cell energy supply and in the activity of the antioxidant system, as well as an increase in the level of lipid hydroperoxides and diene conjugates. This led to a reduction of the necrosis zone in the myocardium and disturbances in the heart rhythm. The blocker of the mitochondrial ATP-dependent potassium (mitoK

Indexed as

Acute DiseaseAdenosine TriphosphateAnimalsAntioxidantsArrhythmias, CardiacDisease Models, AnimalLipid PeroxidationMaleMyocardial Reperfusion InjuryMyocardiumPotassium ChannelsRatsRats, WistarTachycardiaUridineUridine DiphosphateAdenosine TriphosphateAntioxidantsmitochondrial K(ATP) channelPotassium ChannelsUridineUridine DiphosphateUridine Triphosphate

Identifiers

PMID34417540
PMCPMC8379228
OpenAlexW3194840143

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.